Tensive

Tensive is pleased to announce new data confirming the potential of its REGENERA™ / SOFTAG™ candidate device to transform post-cancer breast reconstruction.

Here are the highlights we found:

• Strong safety profile and growing performance benefits of the device in clinical data from two ongoing trials in patients undergoing lumpectomy.
• High levels of patient and surgeon satisfaction in an interim analysis in our pivotal trial, which met primary safety and secondary performance objectives.
• The device was supportive in identifying the tumor bed, enabling the guiding of radiotherapy, according to an interim analysis of a separate cohort.
• Durable satisfaction with the device following lumpectomy reconstruction in three-year follow-up results in our first-in-human study.

Of the 2.1 million lumpectomies performed worldwide each year, 1.6 million are not reconstructed, because of a lack of viable options. Tensive is developing its REGENERA™ / SOFTAG™ candidate device to fill that substantial unmet medical need.

REGENERA™ / SOFTAG™ is gradually absorbed by the body, enabling the patient’s own healthy tissue to regrow. The result is restoration composed of natural tissue that preserves the original shape and feel of the patient’s breast shape and feel.

In addition, the implant is clearly differentiated from surrounding tissue on diagnostic imaging, supporting more targeted delivery of radiotherapy.

To read more about our solutions, go to www.tensive.com
For a link to our press release, please click on https://www.tensive.com/tensive-provides-positive-clinical-updates-highlighting-potential-of-regenera-softag-device-to-transform-post-cancer-breast-reconstruction/

We are thrilled to announce our €14M Series A funding round led by Panakès Partners SGR to transform breast reconstruction following lumpectomy.

This milestone marks a transformative step forward in our mission to revolutionize breast reconstruction and augmentation through our innovative bio-absorbable implant technology, creating new opportunities to advance women’s health and breast care.

We are enthusiastic to welcome the support of Panakès Partners, the EIC Fund, and other esteemed investors who share our vision of improving the quality of life for breast cancer survivors worldwide.

We are also excited to welcome Dr. Sanjay Kakkar as our new CEO, bringing invaluable leadership and experience to drive Tensive’s growth and expansion.

This achievement brings us closer to making a lasting impact, reinforcing our commitment to restoring confidence and femininity, and improving the quality of life for breast cancer patients.

Read more about our Series A round here: https://www.tensivemed.com/tensive-raises-14m-series-a-financing-round/

Tensive raises €14,000,000 Series A Financing Round led by Panakès Partners SGR to transform breast reconstruction following lumpectomy. Appoints Sanjay Kakkar as Chief Executive Officer | Tensive Tensive raises €14,000,000 Series A Financing Round led by Panakès Partners SGR to transform breast reconstruction following lumpectomy.

We're thrilled to announce an exciting opportunity to join our team as a Site Manager in Milan! If you're dedicated to quality and excited about working in a dynamic environment, this is the role for you. This position offers the chance to contribute to a noble mission.

Learn more and apply today: www.tensivemed.com/careers/site-manager-open/

Site Manager (Open) | Tensive Tensive is looking for a highly skilled Site Manager for its headquarters in Milan, Italy.